Tumour marker	Paper	Summary
IGF‐1	Bese Add paper	No correlation with disease
CA125 + b2m	Hernádi 1992	b2m has low specificity for detection of ovarian cancer. CA125 performs better
CA72.4	Fayed 1998	Added to CA125 it improves sensitivity and specificity for detecting recurrence, especially in mucinous tumours
CEA	Khoo 1974 Khoo 1979 Lenehan 1986	Persistently low levels are consistent with a good prognosis Serial samples were useful in predicting relapse in a small number of women; clinical role is limited to a small subset of patients
CA72.4, CA19.9	Fioretti 1992	Useful for detecting recurrence in patients with normal CA125 at diagnosis
PLAP‐A, PLAP‐C	Fisken 1989	No correlation with disease
Anti‐p53	Gadducci 1995	Not clinically useful
CYFRA 21‐1	Gadducci 1998
D‐dimer	Gadducci 2001
Urinary neopterine	Hetzel 1983
TPA	Inoue 1985	Lacks tumour specificity
SLX	Iwanari 1989	May be of benefit in combination with CA125
CA125 + CA15.3 + CA72.4 + SCC + 90K	Garzetti 1991	Includes all gynaecological malignancies. CA125 plus 90K identified 86% of recurrences
CA125 + CEA + ferritin + TPA	Lahousen 1987	If normal can avoid second look laparotomy
CA125 + CASA	Oehler 1999	CASA less sensitive than CA125, CASA may be useful when CA125 inconclusive
Sialyl Le(x)‐i	Kobayashi 1989	Upto 96% showed rise in levels with tumour progression
OPN	Schorge 2004	Inferior to CA125 in determining response to treatment, but showed an earlier rise in recurrent disease
CA125 + TPS	Sliutz 1995	Improved detection of recurrence when compared to CA125 alone
IAP	Shimizu 1986	May have a role in early detection of recurrence
TPS	Tempfer 1998 Zakrzewska 2000	TPS is useful, but cannot replace CA125 TPS may rise before CA125 rises in women with recurrence